The Danish biotech firm exceeded first-quarter revenue expectations and announced a share repurchase program worth DKK 1.3 billion.
Zealand Pharma’s stock surged 12% after reporting first-quarter revenue that surpassed analyst estimates. The company also unveiled a DKK 1.3 billion share buyback program, signaling confidence in its financial position.
Revenue growth outpaced expectations, though specific figures were not disclosed in the initial update. The buyback plan follows a strong quarter, reflecting management’s optimism about future cash flows and operational performance.
Shares rose sharply in early trading, reflecting investor approval of the financial results and capital return strategy.